Karuna Therapeutics was a clinical-stage biopharmaceutical company that developed novel treatments for psychiatric and neurological disorders. The company's lead candidate, KarXT, showed promise in treating schizophrenia and other psychiatric conditions by targeting muscarinic receptors. Karuna's innovative approach to psychiatric drug development attracted significant attention from investors and the pharmaceutical industry. In December 2023, Bristol Myers Squibb acquired Karuna for approximately $14 billion.
Karuna Therapeutics has received investment from 2 venture capital firms.
A clinical-stage biopharmaceutical company focused on developing novel therapies for psychiatric and neurological conditions.
Karuna Therapeutics has received investment from PureTech Health, Third Rock Ventures. These venture capital firms and investors provide both capital and strategic support.
Karuna Therapeutics was founded in 2009 and is headquartered in Boston, MA.
Karuna Therapeutics operates in the Biotech sector. A clinical-stage biopharmaceutical company focused on developing novel therapies for psychiatric and neurological conditions.
